EYE:NASDAQNational Vision Holdings, Inc. Analysis
Data as of 2026-04-01 - not real-time
$23.92
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
National Vision delivered a solid Q4 2025 performance, with revenue climbing 9% to $1.99 billion and operating income surging 56%, underscoring the 15% year‑over‑year revenue growth trend. The company’s gross margin remains robust at roughly 58.8% while operating margin has nudged up to 1.75%, and forward EPS is projected at $1.25, a dramatic lift from the trailing $0.37. Despite these fundamentals, the stock trades at $23.92, well below the DCF‑derived fair value of $26.84, implying a potential upside of about 47%. Technical gauges are mixed: the 20‑day SMA (≈26.9) and 50‑day SMA (≈27.1) sit above price, the RSI is in the 37‑range suggesting modest oversold pressure, and a bearish MACD histogram reinforces short‑term downside bias. Volume is on an increasing trend, providing liquidity support as the market digests the earnings beat.
The valuation picture tilts toward the undervalued side given the sizeable upside and a forward P/E of ~19 versus a trailing P/E of ~65, though the lack of a dividend makes income‑focused investors look elsewhere. High beta (~1.2) and 30‑day volatility above 60% flag elevated market risk, especially in the consumer‑cyclical sector which is sensitive to discretionary spending. Nonetheless, the company’s strong cash flow generation, expanding store sales, and favorable industry dynamics support a medium‑ to long‑term buy case, while the near‑term technical landscape suggests a cautious hold.
The valuation picture tilts toward the undervalued side given the sizeable upside and a forward P/E of ~19 versus a trailing P/E of ~65, though the lack of a dividend makes income‑focused investors look elsewhere. High beta (~1.2) and 30‑day volatility above 60% flag elevated market risk, especially in the consumer‑cyclical sector which is sensitive to discretionary spending. Nonetheless, the company’s strong cash flow generation, expanding store sales, and favorable industry dynamics support a medium‑ to long‑term buy case, while the near‑term technical landscape suggests a cautious hold.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Recent earnings beat but price below key moving averages
- Bearish MACD and modest oversold RSI
- Elevated volatility and beta increasing short‑term risk
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF upside of ~47% and forward P/E compression
- Strong revenue growth and improving operating margins
- Increasing trading volume indicating market interest
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Sustainable demand for vision care and recurring revenue from eye‑exam services
- Robust cash flow generation supporting strategic expansion
- Competitive positioning in the specialty retail segment with diversified brand portfolio
Key Metrics & Analysis
Financial Health
Revenue Growth15.10%
Profit Margin1.49%
P/E Ratio64.6
ROE3.51%
ROA2.08%
Debt/Equity79.88
P/B Ratio2.2
Op. Cash Flow$146.3M
Free Cash Flow$109.9M
Technical Analysis
TrendNeutral
RSI37.7
Support$23.86
Resistance$29.84
MA 20$26.90
MA 50$27.07
MA 200$26.02
MACDBearish
VolumeIncreasing
Fear & Greed Index77.61
Valuation
Fair Value$26.84
Target Price$35.27
Upside/Downside47.46%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.24
Volatility61.77%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.